Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 4:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Connective Tissue Graft Clear all
Terminated Not applicable Interventional

Registry Trial of the Effectiveness of Platelet Rich Plasma for Chronic Non-Healing Wounds

NCT02071979
View directory record Official record
Conditions
Diabetic Foot Ulcers, Venous Ulcers, Pressure Ulcers
Interventions
Autologous PRP Gel, Autologous PRP Injections, Autologous PRP Gel plus PRP Injections, Standard Wound Care
Device · Procedure
Lead sponsor
Arteriocyte, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
6
States / cities
Bakersfield, California • Idaho Falls, Idaho • Englewood, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2018 · Synced Sep 17, 2026, 4:08 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Vertical Soft Tissue Augmentation With CTG vs ADM

NCT05729607
View directory record Official record
Conditions
Implant Complication
Interventions
Vertical soft tissue augmentation
Procedure
Lead sponsor
Harvard Medical School (HMS and HSDM)
Other
Eligibility
18 Years to 99 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 1 Interventional

Stem Cell Transplant With Th2/Tc2 Cells to Treat Advanced Breast Cancer

NCT00079625
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Th2/Tc2 Cells
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Sep 17, 2026, 4:08 AM EDT
Terminated Phase 2 Interventional Results available

A New Micrografting Technique for Vitiligo

NCT01262547
View directory record Official record
Conditions
Vitiligo
Interventions
Dermabrasion-Micrografting, Dermabrasion
Device · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Sep 17, 2026, 4:08 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Pilot Study of the Effect of Laser on Reversing Chronic Radiation Injury

NCT01910818
View directory record Official record
Conditions
Chronic Radiation Dermatitis
Interventions
Fractional CO2 laser treatment, No treatment
Device · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Sep 17, 2026, 4:08 AM EDT
Terminated Phase 1Phase 2 Interventional

Acupuncture Chemotherapy-Induced Peripheral Neuropathy (CIPN) IRG

NCT01815346
View directory record Official record
Conditions
Breast Cancer
Interventions
Acupuncture, Questionnaires, Hand Function and Balance Tests
Procedure · Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

To Compare Different Soft Tissue Grafts at the Time of Lateral Ridge Augmentation Procedure.

NCT03774888
View directory record Official record
Conditions
Bone Graft; Complications, Infection or Inflammation, Ridge Deficency, Dental Implant
Interventions
Connective tissue graft at time of bone graft, Acellular Demal Matrix at time of bone graft, No soft tissue grafting at time of bone graft
Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

A Study in Participants With Moderate to Severe Psoriasis

NCT01107457
View directory record Official record
Conditions
Psoriasis
Interventions
Ixekizumab, Placebo
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
31
States / cities
Bakersfield, California • New Haven, Connecticut • Washington D.C., District of Columbia + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Sep 17, 2026, 4:08 AM EDT
Recruiting Not applicable Interventional

Changes of Soft Tissue Grafting: A Randomized Study

NCT05633511
View directory record Official record
Conditions
Gingival Recession
Interventions
Split Mouth Design
Procedure
Lead sponsor
Tufts University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2036
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Completed No phase listed Observational

The Role of Connective Tissue Growth Factor in the Development of Kidney Disease After Organ Transplantation

NCT00056784
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
4 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients

NCT02649218
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Ligelizumab
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
17
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Not applicable Interventional

Evaluation of Geistlich Fibro-Gide® in Comparison to CTG for the Treatment Around Implants

NCT04703738
View directory record Official record
Conditions
Soft Tissue Defect
Interventions
Soft tissue flap + Connective Tissue Graft, Soft tissue flap + Geistlich Fibro-Gide®
Procedure · Device
Lead sponsor
Geistlich Pharma AG
Industry
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
5
States / cities
Fullerton, California • Aurora, Colorado • Houston, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 1 Interventional

Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic Graft-Versus-Host Disease After Undergoing a Donor Stem Cell Transplant

NCT00361049
View directory record Official record
Conditions
Cancer
Interventions
graft versus host disease prophylaxis/therapy, fluorescence in situ hybridization, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, in vitro-treated bone marrow transplantation, management of therapy complications
Biological · Genetic · Other + 1 more
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
8
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 4, 2010 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 1 Interventional

Safety Study of Antria Cell Preparation Process to Enhance Facial Fat Grafting With Adipose Derived Stem Cells

NCT01828723
View directory record Official record
Conditions
Lipoatrophy, Aging, Wrinkles
Interventions
SVF
Biological
Lead sponsor
Antria
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Greensburg, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Results available

ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab

NCT02296424
View directory record Official record
Conditions
Systemic Juvenile Idiopathic Arthritis (SJIA)
Interventions
ACZ885 150 mg (Canakinumab)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 20 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Los Angeles, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 8, 2019 · Synced Sep 17, 2026, 4:08 AM EDT
Recruiting Not applicable Interventional

Rising Tide - Amniotic Tissue(s) Treatments for Chronic Diabetic Foot Ulcers

NCT06681428
View directory record Official record
Conditions
Diabetic Foot Ulcer (DFU), Chronic Foot Ulcers
Interventions
Allograft
Other
Lead sponsor
Tides Medical
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
9
States / cities
Fresno, California • Los Angeles, California • Vista, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Sep 17, 2026, 4:08 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Suprathel Versus Xeroform for the Management of Skin Graft Donor Sites

NCT04014400
View directory record Official record
Conditions
Burns, Skin Graft Complications, Skin; Deformity
Interventions
Suprathel or Xeroform donor site application
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
31 Days to 80 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Not applicable Interventional Results available

Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant

NCT00408681
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Atypical Chronic Myeloid Leukemia, Breakpoint Cluster Region-abl Translocation (BCR-ABL) Negative, Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Disseminated Neuroblastoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Gastrointestinal Complications, Juvenile Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Poor Prognosis Metastatic Gestational Trophoblastic Tumor, Previously Treated Childhood Rhabdomyosarcoma, Primary Myelofibrosis, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Neuroblastoma, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Small Lymphocytic Lymphoma, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Splenic Marginal Zone Lymphoma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage II Ovarian Epithelial Cancer, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Malignant Testicular Germ Cell Tumor, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Ovarian Epithelial Cancer, Stage III Small Lymphocytic Lymphoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Breast Cancer, Stage IV Chronic Lymphocytic Leukemia, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Ovarian Epithelial Cancer, Stage IV Small Lymphocytic Lymphoma
Interventions
lithium carbonate, laboratory biomarker analysis
Drug · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 1Phase 2 Interventional

Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon

NCT00010283
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
beclomethasone dipropionate
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
5 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 1, 2010 · Synced Sep 17, 2026, 4:08 AM EDT
Terminated Phase 3 Interventional Results available

Combination Therapy With 5-Fluorouracil and Photodynamic Therapy in Post-transplant Premalignant Skin Disease

NCT01525329
View directory record Official record
Conditions
Actinic Keratosis, Organ or Tissue Transplant; Complications
Interventions
5-Fluorouracil
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Not applicable Interventional

Comparative Study of Amniotic Membrane Wound Graft In the Management of Diabetic Foot Ulcers

NCT01552499
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Standard of care, Applications of EpiFix
Other
Lead sponsor
MiMedx Group, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Timeline
2012
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 16, 2015 · Synced Sep 17, 2026, 4:08 AM EDT
Terminated Phase 1 Interventional Results available

Targeted Investigation of Microbiome Elimination

NCT05177328
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
S. hominis A 9 Product, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 17, 2026, 4:08 AM EDT
Withdrawn No phase listed Observational

Early Detection of Graft-Versus-Host Disease in Patients Undergoing a Donor Bone Marrow Transplant

NCT00898612
View directory record Official record
Conditions
Lymphoma
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 9, 2014 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Results available

A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis

NCT01186744
View directory record Official record
Conditions
Psoriasis
Interventions
CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
666 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
50
States / cities
Mobile, Alabama • Tucson, Arizona • Fremont, California + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2018 · Synced Sep 17, 2026, 4:08 AM EDT